Turning a corner: Private market posts best month in yearsCore private market metrics suggest positive momentum is brewing and investor sentiment is improving
Turning a corner: Private market posts best month in years
Trading
Data
Solutions
Insights
About
mineralystx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $159.18MM
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone levels. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension. The company has plans for the continued research and development of lorundrostat in hypertension and other potential indications. Mineralys Therapeutics was founded in 2019, and is headquartered in Radnor, Pennsylvania.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Mineralys.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.
